{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:33:48Z","timestamp":1790980428822,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Several studies have reported the association between polymorphisms in Matrix metalloproteinases (MMPs) gene family and risk of Multiple sclerosis (MS). However, the results have been inconsistent and inconclusive. To resolve this issue, here we performed a systematic review and meta-analysis of the MMP-91562 C\/T (rs3918242), MMP-3 (\u2212\u20091612 5A\/6A), and MMP-2 (\u2212\u20091306 C\/T) polymorphisms and susceptibility to MS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a comprehensive systematic search in the major electronic database, including Scopus and PubMed to look up for relevant studies published before December 2019 that surveyed the association between the MMP-91562 C\/T (rs3918242), MMP-3 (\u2212\u20091612 5A\/6A), and MMP-2 (\u2212\u20091306 C\/T) polymorphisms and susceptibility to MS. The level of association between the polymorphisms and susceptibility to MS in the polled analysis was determined by calculating the odds ratio (OR) and the corresponding 95% confidence interval (CI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We found 15 studies containing 2430 MS subjects and 2304 controls. A statistically significant association was observed in the all five comparisons of the MMP-91562 C\/T polymorphism and MS risk as follows: dominant model (OR\u2009=\u20091.62, 95% CI\u2009=\u20091.03\u20132.53,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.03), recessive model (OR\u2009=\u20092.69, 95% CI\u2009=\u20091.68\u20134.29,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), allelic model (OR\u2009=\u20091.51, 95% CI\u2009=\u20091\u20132.28,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.04), TT vs. CC model (OR\u2009=\u20093.20, 95% CI\u2009=\u20091.87\u20135.46,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), and CT vs. CC model (OR\u2009=\u20091.53, 95% CI\u2009=\u20091.02\u20132.28,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.04).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our meta-analysis revealed significant association of MMP-9 (\u2212\u20091562 C\/T) Single-nucleotide polymorphism (SNP) with MS susceptibility that increased the disease risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-020-01804-2","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T05:02:43Z","timestamp":1590728563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Matrix metalloproteinases (MMPs) family gene polymorphisms and the risk of multiple sclerosis: systematic review and meta-analysis"],"prefix":"10.1186","volume":"20","author":[{"given":"Mina","family":"Mohammadhosayni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arezou","family":"Khosrojerdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keivan","family":"Lorian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Aslani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyal","family":"Imani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahman","family":"Razi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Babaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahram","family":"Torkamandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,29]]},"reference":[{"issue":"6","key":"1804_CR1","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/iji.12401","volume":"45","author":"D Imani","year":"2018","unstructured":"Imani D, et al. Association of nod-like receptor protein-3 single nucleotide gene polymorphisms and expression with the susceptibility to relapsing\u2013remitting multiple sclerosis. Int J Immunogenet. 2018;45(6):329\u201336.","journal-title":"Int J Immunogenet"},{"issue":"14","key":"1804_CR2","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1177\/1352458514544537","volume":"20","author":"GR Campbell","year":"2014","unstructured":"Campbell GR, Worrall JT, Mahad DJ. The central role of mitochondria in axonal degeneration in multiple sclerosis. Mult Scler J. 2014;20(14):1806\u201313.","journal-title":"Mult Scler J"},{"issue":"1","key":"1804_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4103\/0976-500X.77118","volume":"2","author":"S Sharma","year":"2011","unstructured":"Sharma S, et al. Fingolimod (FTY720): first approved oral therapy for multiple sclerosis. J Pharmacol Pharmacother. 2011;2(1):49.","journal-title":"J Pharmacol Pharmacother"},{"key":"1804_CR4","doi-asserted-by":"publisher","first-page":"551","DOI":"10.5604\/01.3001.0010.3836","volume":"71","author":"J Kami\u0144ska","year":"2017","unstructured":"Kami\u0144ska J, et al. Multiple sclerosis-etiology and diagnostic potential. Postepy Hig Med Dosw (Online). 2017;71:551\u201363.","journal-title":"Postepy Hig Med Dosw (Online)"},{"key":"1804_CR5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.msard.2019.08.013","volume":"35","author":"R Emamnejad","year":"2019","unstructured":"Emamnejad R, et al. Circulating mesenchymal stem cells, stromal derived factor (SDF)-1 and IP-10 levels increased in clinically active multiple sclerosis patients but not in clinically stable patients treated with beta interferon. Mult Scler Relat Disord. 2019;35:233\u20138.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"1804_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12017-016-8422-x","volume":"19","author":"S Aslani","year":"2017","unstructured":"Aslani S, et al. Epigenetic modifications and therapy in multiple sclerosis. NeuroMolecular Med. 2017;19(1):11\u201323.","journal-title":"NeuroMolecular Med"},{"issue":"6","key":"1804_CR7","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1177\/1352458509104592","volume":"15","author":"C Hawkes","year":"2009","unstructured":"Hawkes C, Macgregor A. Twin studies and the heritability of MS: a conclusion. Mult Scler J. 2009;15(6):661\u20137.","journal-title":"Mult Scler J"},{"issue":"10","key":"1804_CR8","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/j.1468-1331.2008.02262.x","volume":"15","author":"H Kuusisto","year":"2008","unstructured":"Kuusisto H, et al. Concordance and heritability of multiple sclerosis in Finland: study on a nationwide series of twins. Eur J Neurol. 2008;15(10):1106\u201310.","journal-title":"Eur J Neurol"},{"issue":"11","key":"1804_CR9","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1177\/1352458514564492","volume":"21","author":"C Fagnani","year":"2015","unstructured":"Fagnani C, et al. Twin studies in multiple sclerosis: a meta-estimation of heritability and environmentality. Mult Scler J. 2015;21(11):1404\u201313.","journal-title":"Mult Scler J"},{"issue":"7","key":"1804_CR10","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/sj.gene.6363706","volume":"1","author":"K Vandenbroeck","year":"2000","unstructured":"Vandenbroeck K, et al. High-resolution analysis of IL-6 minisatellite polymorphism in Sardinian multiple sclerosis: effect on course and onset of disease. Genes Immun. 2000;1(7):460.","journal-title":"Genes Immun"},{"issue":"7","key":"1804_CR11","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.autrev.2009.02.009","volume":"8","author":"J Smolders","year":"2009","unstructured":"Smolders J, et al. The relevance of vitamin D receptor gene polymorphisms for vitamin D research in multiple sclerosis. Autoimmun Rev. 2009;8(7):621\u20136.","journal-title":"Autoimmun Rev"},{"issue":"8","key":"1804_CR12","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1007\/s00415-005-0795-y","volume":"252","author":"F Matesanz","year":"2005","unstructured":"Matesanz F, et al. Protein tyrosine phosphatase gene (PTPN22) polymorphism in multiple sclerosis. J Neurol. 2005;252(8):994\u20135.","journal-title":"J Neurol"},{"issue":"4","key":"1804_CR13","doi-asserted-by":"publisher","first-page":"e61032","DOI":"10.1371\/journal.pone.0061032","volume":"8","author":"EA Sokolova","year":"2013","unstructured":"Sokolova EA, et al. Association of SNPs of CD40 gene with multiple sclerosis in Russians. PLoS One. 2013;8(4):e61032.","journal-title":"PLoS One"},{"issue":"1\u20132","key":"1804_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jns.2006.11.021","volume":"259","author":"VW Yong","year":"2007","unstructured":"Yong VW, et al. Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators. J Neurol Sci. 2007;259(1\u20132):79\u201384.","journal-title":"J Neurol Sci"},{"issue":"4","key":"1804_CR15","first-page":"296","volume":"15","author":"MR Javan","year":"2016","unstructured":"Javan MR, et al. Downregulation of immunosuppressive molecules, PD-1 and PD-L1 but not PD-L2, in the patients with multiple sclerosis. Iran J Allergy Asthma Immunol. 2016;15(4):296\u2013302.","journal-title":"Iran J Allergy Asthma Immunol"},{"issue":"2","key":"1804_CR16","first-page":"91","volume":"3","author":"M-R Javan","year":"2014","unstructured":"Javan M-R, et al. Molecular analysis of interleukin-25 exons 1 and 2 and its serum levels in Iranian patients with multiple sclerosis. Am J Clin Exp Immunol. 2014;3(2):91.","journal-title":"Am J Clin Exp Immunol"},{"issue":"5","key":"1804_CR17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/01616412.2017.1301623","volume":"39","author":"MR Javan","year":"2017","unstructured":"Javan MR, et al. An interleukin 12 B single nucleotide polymorphism increases IL-12p40 production and is associated with increased disease susceptibility in patients with relapsing-remitting multiple sclerosis. Neurol Res. 2017;39(5):435\u201341.","journal-title":"Neurol Res"},{"issue":"1","key":"1804_CR18","first-page":"128","volume":"36","author":"S-O Yoon","year":"2003","unstructured":"Yoon S-O, et al. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol. 2003;36(1):128\u201337.","journal-title":"J Biochem Mol Biol"},{"issue":"5","key":"1804_CR19","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/S0955-0674(98)80035-5","volume":"10","author":"SD Shapiro","year":"1998","unstructured":"Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol. 1998;10(5):602\u20138.","journal-title":"Curr Opin Cell Biol"},{"issue":"5\u20136","key":"1804_CR20","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S0736-5748(99)00010-6","volume":"17","author":"SK Chintala","year":"1999","unstructured":"Chintala SK, Tonn JC, Rao JS. Matrix metalloproteinases and their biological function in human gliomas. Int J Dev Neurosci. 1999;17(5\u20136):495\u2013502.","journal-title":"Int J Dev Neurosci"},{"key":"1804_CR21","doi-asserted-by":"crossref","unstructured":"Cui N, Hu M, Khalil RA. Biochemical and biological attributes of matrix metalloproteinases. In Progress in molecular biology and translational science. Vol. 147. Academic Press; 2017. p. 1\u201373.","DOI":"10.1016\/bs.pmbts.2017.02.005"},{"issue":"sup1","key":"1804_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3109\/14756366.2016.1161620","volume":"31","author":"A Jab\u0142o\u0144ska-Trypu\u0107","year":"2016","unstructured":"Jab\u0142o\u0144ska-Trypu\u0107 A, Matejczyk M, Rosochacki S. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J Enzyme Inhib Med Chem. 2016;31(sup1):177\u201383.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"7","key":"1804_CR23","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/35081571","volume":"2","author":"VW Yong","year":"2001","unstructured":"Yong VW, et al. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci. 2001;2(7):502.","journal-title":"Nat Rev Neurosci"},{"issue":"7","key":"1804_CR24","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S0945-053X(00)00102-5","volume":"19","author":"S Ye","year":"2000","unstructured":"Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol. 2000;19(7):623\u20139.","journal-title":"Matrix Biol"},{"issue":"17","key":"1804_CR25","first-page":"4225","volume":"59","author":"Y Kanamori","year":"1999","unstructured":"Kanamori Y, et al. Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion\/deletion polymorphism in its promoter region. Cancer Res. 1999;59(17):4225\u20137.","journal-title":"Cancer Res"},{"issue":"5","key":"1804_CR26","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1016\/j.juro.2009.01.012","volume":"181","author":"ST dos Reis","year":"2009","unstructured":"dos Reis ST, et al. Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer. J Urol. 2009;181(5):2320\u20135.","journal-title":"J Urol"},{"issue":"1\u20132","key":"1804_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jneuroim.2009.06.014","volume":"214","author":"D Mirowska-Guzel","year":"2009","unstructured":"Mirowska-Guzel D, et al. Association of MMP1, MMP3, MMP9, and MMP12 polymorphisms with risk and clinical course of multiple sclerosis in a polish population. J Neuroimmunol. 2009;214(1\u20132):113\u20137.","journal-title":"J Neuroimmunol"},{"issue":"6","key":"1804_CR28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/08820139.2016.1180303","volume":"45","author":"Z Rahimi","year":"2016","unstructured":"Rahimi Z, et al. Functional promoter polymorphisms of MMP-2 C-735T and MMP-9 C-1562T and their synergism with MMP-7 A-181G in multiple sclerosis. Immunol Investig. 2016;45(6):543\u201352.","journal-title":"Immunol Investig"},{"issue":"1","key":"1804_CR29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S0165-5728(00)00189-2","volume":"105","author":"I Nelissen","year":"2000","unstructured":"Nelissen I, et al. Polymorphism analysis suggests that the gelatinase B gene is not a susceptibility factor for multiple sclerosis. J Neuroimmunol. 2000;105(1):58\u201363.","journal-title":"J Neuroimmunol"},{"issue":"4","key":"1804_CR30","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264\u20139.","journal-title":"Ann Intern Med"},{"issue":"9","key":"1804_CR31","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"issue":"2","key":"1804_CR32","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","volume":"11","author":"TB Huedo-Medina","year":"2006","unstructured":"Huedo-Medina TB, et al. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11(2):193.","journal-title":"Psychol Methods"},{"issue":"3","key":"1804_CR33","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"issue":"4","key":"1804_CR34","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719\u201348.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"1804_CR35","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"Colin B. Begg","year":"1994","unstructured":"Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088\u2013101.","journal-title":"Biometrics"},{"issue":"7109","key":"1804_CR36","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, et al. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997;315(7109):629\u201334.","journal-title":"Bmj"},{"issue":"1\u20132","key":"1804_CR37","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jneuroim.2007.06.022","volume":"189","author":"M \u017divkovi\u0107","year":"2007","unstructured":"\u017divkovi\u0107 M, et al. Matrix metalloproteinase-9\u2212 1562 C\/T gene polymorphism in Serbian patients with multiple sclerosis. J Neuroimmunol. 2007;189(1\u20132):147\u201350.","journal-title":"J Neuroimmunol"},{"issue":"1\u20132","key":"1804_CR38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jneuroim.2008.08.007","volume":"205","author":"Y Bene\u0161ov\u00e1","year":"2008","unstructured":"Bene\u0161ov\u00e1 Y, et al. Matrix metalloproteinase-9 and matrix metalloproteinase-2 gene polymorphisms in multiple sclerosis. J Neuroimmunol. 2008;205(1\u20132):105\u20139.","journal-title":"J Neuroimmunol"},{"issue":"1\u20132","key":"1804_CR39","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jneuroim.2010.04.016","volume":"225","author":"A La Russa","year":"2010","unstructured":"La Russa A, et al. Single nucleotide polymorphism in the MMP-9 gene is associated with susceptibility to develop multiple sclerosis in an Italian case-control study. J Neuroimmunol. 2010;225(1\u20132):175\u20139.","journal-title":"J Neuroimmunol"},{"key":"1804_CR40","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.msard.2016.12.003","volume":"11","author":"A Valado","year":"2017","unstructured":"Valado A, et al. Multiple sclerosis: association of gelatinase B\/matrix metalloproteinase-9 with risk and clinical course the disease. Mult Scler Relat Disord. 2017;11:71\u20136.","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"1804_CR41","first-page":"1697","volume":"48","author":"S Sabbagh","year":"2019","unstructured":"Sabbagh S, et al. Association study between functional polymorphisms of MMP9 gene promoter and multiple sclerosis susceptibility in an Iranian population. Iran J Public Health. 2019;48(9):1697.","journal-title":"Iran J Public Health"},{"issue":"10","key":"1804_CR42","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1134\/S1022795419100107","volume":"55","author":"NKS Sadr","year":"2019","unstructured":"Sadr NKS, et al. Matrix Metalloproteinase-9 gene polymorphisms in south-west Iranian multiple sclerosis (MS) patients. Russ J Genet. 2019;55(10):1266\u201372.","journal-title":"Russ J Genet"},{"key":"1804_CR43","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.msard.2019.04.029","volume":"32","author":"I Ibrahim","year":"2019","unstructured":"Ibrahim I, et al. Matrix metalloproteases 9 rs3918242 gene polymorphism and serum vit D in MS Egyptian patients. Mult Scler Relat Disord. 2019;32:103\u20136.","journal-title":"Mult Scler Relat Disord"},{"issue":"1\u20132","key":"1804_CR44","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jneuroim.2009.07.004","volume":"214","author":"KS Fernandes","year":"2009","unstructured":"Fernandes KS, et al. Matrix metalloproteinase-9 genotypes and haplotypes are associated with multiple sclerosis and with the degree of disability of the disease. J Neuroimmunol. 2009;214(1\u20132):128\u201331.","journal-title":"J Neuroimmunol"},{"issue":"1\u20132","key":"1804_CR45","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jns.2007.09.037","volume":"267","author":"T Djuri\u0107","year":"2008","unstructured":"Djuri\u0107 T, et al. Association of the MMP-3 5A\/6A gene polymorphism with multiple sclerosis in patients from Serbia. J Neurol Sci. 2008;267(1\u20132):62\u20135.","journal-title":"J Neurol Sci"},{"issue":"2","key":"1804_CR46","first-page":"137","volume":"10","author":"Z RAHIMI","year":"2016","unstructured":"RAHIMI Z, ABBASI A, RAHIMI Z. Functional promoter polymorphism of matrix metalloproteinase (MMP)-3 5A\/6A and its interaction with MMP-7 a-181G polymorphism in multiple sclerosis. Biharean Biologist. 2016;10(2):137\u201340.","journal-title":"Biharean Biologist"},{"issue":"2","key":"1804_CR47","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/medicina54020029","volume":"54","author":"R Liutkevi\u010dien\u0117","year":"2018","unstructured":"Liutkevi\u010dien\u0117 R, et al. Association of MMP-2 (\u22121306 C\/T) gene polymorphism with predisposition to optic neuritis and optic neuritis together with multiple sclerosis. Medicina. 2018;54(2):29.","journal-title":"Medicina"},{"issue":"6","key":"1804_CR48","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/jim-2016-000111","volume":"64","author":"D Aksoy","year":"2016","unstructured":"Aksoy D, et al. Analysis of MMP2-1306C\/T and TIMP2G-418C polymorphisms with relapsing remitting multiple sclerosis. J Investig Med. 2016;64(6):1143\u20137.","journal-title":"J Investig Med"},{"key":"1804_CR49","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jneuroim.2015.01.008","volume":"279","author":"S Nischwitz","year":"2015","unstructured":"Nischwitz S, et al. MS susceptibility is not affected by single nucleotide polymorphisms in the MMP9 gene. J Neuroimmunol. 2015;279:46\u20139.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"1804_CR50","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.arcmed.2017.01.001","volume":"48","author":"J Li","year":"2017","unstructured":"Li J, et al. Association study of MMP-9\u2212 1562C\/T gene polymorphism with susceptibility to multiple autoimmune diseases: a meta-analysis. Arch Med Res. 2017;48(1):105\u201312.","journal-title":"Arch Med Res"},{"issue":"4","key":"1804_CR51","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1155\/2006\/709869","volume":"22","author":"E Waubant","year":"2006","unstructured":"Waubant E. Biomarkers indicative of blood-brain barrier disruption in multiple sclerosis. Dis Markers. 2006;22(4):235\u201344.","journal-title":"Dis Markers"},{"issue":"8","key":"1804_CR52","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1096\/fasebj.5.8.1850705","volume":"5","author":"JF Woessner Jr","year":"1991","unstructured":"Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5(8):2145\u201354.","journal-title":"FASEB J"},{"issue":"3","key":"1804_CR53","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0304-3940(95)12173-0","volume":"201","author":"S Chandler","year":"1995","unstructured":"Chandler S, et al. Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett. 1995;201(3):223\u20136.","journal-title":"Neurosci Lett"},{"issue":"4","key":"1804_CR54","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/jnr.490360409","volume":"36","author":"K Gijbels","year":"1993","unstructured":"Gijbels K, et al. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J Neurosci Res. 1993;36(4):432\u201340.","journal-title":"J Neurosci Res"},{"issue":"3","key":"1804_CR55","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1006\/bbrc.1993.1540","volume":"192","author":"P Proost","year":"1993","unstructured":"Proost P, Vandamme J, Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun. 1993;192(3):1175\u201381.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1804_CR56","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0165-5728(92)90192-N","volume":"41","author":"K Gijbels","year":"1992","unstructured":"Gijbels K, et al. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol. 1992;41(1):29\u201334.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"1804_CR57","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1468-1331.1994.tb00051.x","volume":"1","author":"L Paemen","year":"1994","unstructured":"Paemen L, et al. Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases. Eur J Neurol. 1994;1(1):55\u201363.","journal-title":"Eur J Neurol"},{"issue":"3","key":"1804_CR58","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1177\/1352458508099482","volume":"15","author":"Y Bene\u0161ov\u00e1","year":"2009","unstructured":"Bene\u0161ov\u00e1 Y, et al. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult Scler J. 2009;15(3):316\u201322.","journal-title":"Mult Scler J"},{"issue":"1\u20132","key":"1804_CR59","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0014-5793(99)00863-7","volume":"455","author":"S Shimajiri","year":"1999","unstructured":"Shimajiri S, et al. Shortened microsatellite d (CA) 21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene. FEBS Lett. 1999;455(1\u20132):70\u20134.","journal-title":"FEBS Lett"},{"issue":"14","key":"1804_CR60","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1161\/01.CIR.99.14.1788","volume":"99","author":"B Zhang","year":"1999","unstructured":"Zhang B, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation. 1999;99(14):1788\u201394.","journal-title":"Circulation"},{"issue":"5","key":"1804_CR61","first-page":"418","volume":"105","author":"B Zhang","year":"1999","unstructured":"Zhang B, et al. Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12. 2\u201313.1. Hum Genet. 1999;105(5):418\u201323.","journal-title":"Hum Genet"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01804-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-020-01804-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01804-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T19:25:54Z","timestamp":1622229954000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-020-01804-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,29]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1804"],"URL":"https:\/\/doi.org\/10.1186\/s12883-020-01804-2","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,29]]},"assertion":[{"value":"17 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"218"}}